News

Press Releases

Publications

SnoopLigase peptide-peptide conjugation enables modular vaccine assembly 
Andersson AC et al.
Scientific Reports, Mar. 2019. 15;9(1):4625. doi: 10.1038/s41598-019-40985-w.

Combination of RTS,S and Pfs25-IMX313 Induces a Functional Antibody Response Against Malaria Infection and Transmission in Mice. 
Brod F et al.
Frontiers in Immunology, Dec. 2018. 4;9:2780. doi: 10.3389/fimmu.2018.02780.

​Dual Plug-and-Display Synthetic Assembly Using Orthogonal Reactive Proteins for Twin Antigen Immunization. 
Brune KD et al.
Bioconjugate Chemistry, May 2017. 17;28(5):1544-1551. doi: 10.1021/acs.bioconjchem.7b00174.

HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice.
Tomusange K et al.
Scientif Reports, Jun. 2016. 30;6:29131. doi: 10.1038/srep29131.

Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology.
Li Y et al.
Scientific Reports, Jan. 2016. 8;6:18848. doi: 10.1038/srep18848.

T Cell Responses Induced by Adenoviral Vectored Vaccines Can Be Adjuvanted by Fusion of Antigen to the Oligomerization Domain of C4b-Binding Protein.
Forbes EK et al.
PLoS ONE, Sep. 2012. 7(9):e44943. doi:10.1371/journal.pone.0044943.

Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates.
Spencer AJ et al.
PLoS ONE, Mar. 2012. 7(3): e33555. doi:10.1371/journal.pone.0033555.

Immunocontraception in male feral swine treated with a recombinant gonadotropin-releasing hormone vaccine.
Campbell TA,et al.
Journal of Swine Health and Production, May 2010. 18(3):118-124​.

The oligomerization domain of C4-binding protein (C4bp) acts as an adjuvant, and the fusion protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine C4bp domain protects mice against malaria.
Ogun SA et al.
Infection and Immunity, Aug. 2008. 76(8):3817-3823. doi:10.1128/IAI.01369-07.

Effective induction of high-titer antibodies by viral vector vaccines.
Draper SJ et al.
Nature Medicine, Aug. 2008.14(8):819-821. doi: 10.1038/nm.1850.

Events

Vaccine Summit 2021

Virtual – Oral Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide the last clinical results of OVX836 as part of a presentation entitled « OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial ».